Sign In
28 Feb 2013 12:47
ο»Ώ
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Β
Director's Dealing
Β
Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that David Evans, Non Executive Chairman of the Company, has transferred 12,368 ordinary shares from his own name into his pension fund. The shares were transferred at a price of 31.5p
There has been no change in David Evans' beneficial shareholding in Venn as a result of these transactions.
Β Enquiries: Β | |
Venn Life Sciences Holdings Plc | |
Tony Richardson, Chief Executive Officer | Tel: +353 154 99 341 |
Paul Foulger, Finance Director Β | Tel: 020 7245 1100 |
Zeus Capital (Nominated Adviser and Broker) | |
Ross Andrews/Andrew Jones (Corporate Finance) | Tel: 0161 831 1512 |
John Goold (Institutional Sales) Β | Tel: 020 7016 8925 |
Walbrook PR Ltd | Tel: 020 7933 8787 or Mob: 07980 541 893 |
Paul McManus | paul.mcmanus@walbrookpr.com |
Β
Β
Follow the stocks
